Healthcare / BiotechnologyNasdaqGS
$1.79
-0.01 (-0.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-63.5M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$113M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-149.1%
↓Gross Margin
82.8%
↑Debt/Equity
0.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-458.3%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.9M · net income $-79.6M · FCF $-63.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $13.9M | $13.9M | $16.1M | — | — | — | — |
| Net Income | $-79.6M | $-79.6M | $-77.3M | $-73.8M | $-120.7M | $-76.0M | $-12.8M |
| EBITDA | $-79.9M | $-79.9M | $-65.5M | $-80.3M | $-122.8M | $-69.1M | $-12.4M |
| EPS | — | — | -1.32 | -1.85 | -3.65 | -8.95 | — |
| Gross Margin | 82.8% | 82.8% | 97.1% | — | — | — | — |
| Operating Margin | -609.2% | -609.2% | -424.2% | — | — | — | — |
| Net Margin | -574.5% | -574.5% | -478.9% | — | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.35 | 0.35 | 0.17 | 0.17 | 0.12 | — | — |
| Current Ratio | 2.76 | 2.76 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-63.5M | $-63.5M | $-57.9M | $-77.4M | $-95.7M | $-35.9M | $-11.6M |
| Returns | |||||||
| ROE | -149.1% | -149.1% | -64.0% | -58.7% | -75.1% | -29.1% | 82.0% |
| Valuation | |||||||
| P/B | 2.10 | 2.10 | 0.82 | 0.67 | 0.30 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -14.2% | -14.2% | — | — | — | — | — |
| EPS Growth | — | — | 28.6% | 49.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+47.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.32 → n/d
Residual
+47.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.